Dermatologic manifestations and comorbidities in patients with acromegaly or gigantism
DOI:
https://doi.org/10.29176/2590843X.982Keywords:
Acromegaly, gigantism, skin manifestations, skin.Abstract
Introduction: Acromegaly and gigantism are diseases caused by an excessive production of growth hormone. Most of patients who suffer these conditions are affected with skin changes, as well as comorbidities increasing their morbidity and mortality.
Objective: To describe the dermatological manifestations and associated comorbidities in patients with acromegaly and gigantism.
Methods: A descriptive cross-sectional study was developed, which evaluated and described the dermatological features and systemic diseases associated in patients with acromegaly and gigantism valued in endocrinology in Manizales and Armenia in the the period April to May, 2013.
Results: The dermatological findings and associated comorbidities in 20 patients with acromegaly and 2 with gigantism are described; a pituitary adenoma was demonstrated in all of them. The findings were as follows: thickening of skin and scalp , 77.3% of patients; acral enlargement, 95.5%; enlarged nose , 81.8%; enlarged ears , 27.3%; enlarged lips, 50%; macroglossia, 54.5%; likewise, frontal bossing was found in 63.6%, prognathism and malocclusion in 68.2%, among others. Systemic diseases were associated in 63.6%, mainly hypertension in 50%, diabetes in 27.3% and dyslipidemia in 45.5%.
Conclusion: The population analyzed in this study does not differ from that described in medical literature; the findings support the high frequency of dermatological manifestations and associated comorbidities in these patients and its importance at the time of clinical approach, allowing to suspect the disease and may lead to an early diagnosis that will impact positively morbidity and mortality.
Author Biographies
Wilson Galvis-Franco
Médico dermatólogo; docente, Universidad de Antioquia, Medellín
Humberto Ignacio Franco
Médico endocrinólogo; docente, Universidad de Caldas, Manizales
Alín Abreu-Lomba
Médico endocrinólogo, Centro Médico Imbanaco, Cali
Consuelo Vélez Álvarez
Enfermera, epidemióloga, Ph. D. en Salud Pública; docente, Universidad de Caldas, Manizales, Colombia
References
Adelman DT, Liebert K, Nachtigall LB, Lamerson M, Bakker B. Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med. 2013;6:31-8.
https://doi.org/10.2147/IJGM.S38594
Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3:1-17.
https://doi.org/10.1186/1750-1172-3-17
Holdaway IM, Rajasoorya C. Epidemiology of acro¬megaly. Pituitary. 1999;2:29-41.
https://doi.org/10.1023/A:1009965803750
Daly AF, Rixhon M, Adam C, Dempegioti A, Ticho¬mirowa MA, Beckers A. High prevalence of pitui¬tary adenomas: Across-sectional study in the pro¬vince of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769-75.
https://doi.org/10.1210/jc.2006-1668
Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and bio¬chemical features in 500 patients. Medicine (Balti-more). 1994;73:233-40.
https://doi.org/10.1097/00005792-199409000-00001
Resende M, Bolfi F, dos Santos-Nunes V, Amante-Miot H. Prevalence of dermatologic disorders in 15 patients with acromegaly. An Bras Dermatol. 2012;87:166-8.
https://doi.org/10.1590/S0365-05962012000100031
Kalus A, Chien A, Olerud J. Diabetes mellitus and other endocrine diseases. Acromegaly. In: Klaus Wolff, Lowell Goldsmith, Stephen Katz, Barbara Gilchrest, Amy Paller. Fitzpatrick's Dermatology in General Medicine. 7th. Edition. McGraw Hill companies. pag. 1461-84.
Ben-Shlomo A, Melmed S. Skin manifestations in acromegaly. Clin Dermatol. 2006;24:256-9.
https://doi.org/10.1016/j.clindermatol.2006.04.011
Centurión SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol. 2002,41:631-4.
https://doi.org/10.1046/j.1365-4362.2002.01638.x
Dahbar M, Danilowicz K,Malavela M, Velásquez D, Allevato M, Cabrera H, et al. Manifestaciones cutáneas en la acromegalia. Dermatol Argent. 2009;15:186-90.
Lioté F, Orcel P. Osteoarticular disorders of en¬docrine origin. Best Pract Res Clin Rheumatol. 2000;14:251-76.
https://doi.org/10.1053/berh.2000.0064
Lieberman SA, Björkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acrome¬galy. Endocrinol Metab Clin North Am. 1992;21:615-31.
https://doi.org/10.1016/S0889-8529(18)30205-6
Kamenicky P, Viengchareun S, Blanchard A, Me¬duri G, Zizzari P, Imbert-Teboul M, et al. Epithelial sodium channel is a key mediator of growth hor¬mone-induced sodium retention in acromegaly. Endocrinology. 2008;149:3294-305.
https://doi.org/10.1210/en.2008-0143
Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, IudiceFL, et al. Cardiovascular involvement in patients affected by acromegaly: An appraisal. Int J Cardiol. 2013;167:1712-8.
https://doi.org/10.1016/j.ijcard.2012.11.109
Attal P, Chanson P. Endocrine aspects of obs¬tructive sleep apnea. J Clin Endocrinol Metab. 2010;95:483-95.
https://doi.org/10.1210/jc.2009-1912
Jenkins PJ, Sohaib SA, Akker S, Phillips RR, Spi¬llane K, Wass JA, et al. The pathology of median neuropathy in acromegaly. Ann Intern Med. 2000;133:197-201.
https://doi.org/10.7326/0003-4819-133-3-200008010-00011
Ruiz R, Durán EG, Arellano SA, Sánchez V, Mo¬reno OT, Mendoza F. Acromegalia. Med Int Mex. 2009;25:468-80.
Berg C, Petersenn S, Lahner H, Herrmann BL, Bu¬chfelder M, Droste M, et al. Cardiovascular risk fac¬tors in patients with uncontrolled and long-term acromegaly: Comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95:3648-56.
https://doi.org/10.1210/jc.2009-2570
Dutta P, Bhansali A, Vaiphei K, Dutta U, Ravi Kumar P, Masoodi S, et al. Colonic neoplasia in acromegaly: Increased proliferation or deceased apoptosis? Pituitary. 2012;15:166-73.
https://doi.org/10.1007/s11102-011-0300-9
Andersen M. Management of endocrine disease: GH excess: Diagnosis and medical therapy. Eur J Endocrinol. 2013;170:31-41.
https://doi.org/10.1530/EJE-13-0532
Rúa C, Latorre G, Campuzano G. Diagnóstico de acromegalia. Medicina y Laboratorio. 2011;17:511-531.
Kannan S, Kennedy L. Diagnosis of acrome¬galy: State of the art. Expert Opin Med Diagn. 2013;7:443-53.
https://doi.org/10.1517/17530059.2013.820181
Scacchi M, Cavagnini F. Acromegaly. Pituitary. 2006;9:297-303.
https://doi.org/10.1007/s11102-006-0409-4
Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, PasseriM, et al. Long-term treatment of soma¬tostatin analog-refractory growth hormone-secre¬ting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: A retrospective analysis of clinical practice and outcomes. J ExpClin Cancer Res. 2013;32:1-11.
https://doi.org/10.1186/1756-9966-32-40
Pita-Gutiérrez F, Pertega-Díaz S, Pita-Fernández S, Pena L, Lugo G, Sangiao-Alvarellos S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: A systematic review and meta-analysis. PLoS One. 2013;8:e61523.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
